当前位置: X-MOL 学术Adv. Drug Deliver. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines
Advanced Drug Delivery Reviews ( IF 16.1 ) Pub Date : 2022-07-03 , DOI: 10.1016/j.addr.2022.114417
Takashi Nakamura 1 , Yusuke Sato 1 , Yuma Yamada 1 , Mahmoud M Abd Elwakil 1 , Seigo Kimura 1 , Mahmoud A Younis 2 , Hideyoshi Harashima 1
Affiliation  

A new era of nanomedicines that involve nucleic acids/gene therapy has been opened after two decades in 21st century and new types of more efficient drug delivery systems (DDS) are highly expected and will include extrahepatic delivery. In this review, we summarize the possibility and expectations for the extrahepatic delivery of small interfering RNA/messenger RNA/plasmid DNA/genome editing to the spleen, lung, tumor, lymph nodes as well as the liver based on our studies as well as reported information. Passive targeting and active targeting are discussed in in vivo delivery and the importance of controlled intracellular trafficking for successful therapeutic results are also discussed. In addition, mitochondrial delivery as a novel strategy for nucleic acids/gene therapy is introduced to expand the therapeutic dimension of nucleic acids/gene therapy in the liver as well as the heart, kidney and brain.



中文翻译:

体内脂质纳米颗粒的肝外靶向和未来纳米药物的细胞内靶向

二十一世纪二十年后,一个涉及核酸/基因治疗的纳米药物新时代已经开启,人们高度期待新型更高效的药物递送系统(DDS),并将包括肝外递送。在这篇综述中,我们根据我们的研究和报道,总结了小干扰 RNA/信使 RNA/质粒 DNA/基因组编辑肝外递送至脾脏、肺、肿瘤、淋巴结和肝脏的可能性和期望信息。体内讨论被动靶向和主动靶向还讨论了递送和控制细胞内运输对于成功治疗结果的重要性。此外,引入线粒体递送作为核酸/基因治疗的新策略,以扩大核酸/基因治疗在肝脏以及心脏、肾脏和大脑中的治疗范围。

更新日期:2022-07-03
down
wechat
bug